Bretto Elisabetta, D'Amico Ferdinando, Fiore Walter, Tursi Antonio, Danese Silvio
Gastroenterology and Endoscopy, IRCCS San Raffaele Hospital and Vita-Salute San Raffaele University, 20132 Milan, Italy.
Department of Biomedical Sciences, Humanitas University, 20090 Pieve Emanuele, Italy.
J Clin Med. 2022 Mar 30;11(7):1916. doi: 10.3390/jcm11071916.
Diverticular disease (DD) is a common gastrointestinal condition. Patients with DD experience a huge variety of chronic nonspecific symptoms, including abdominal pain, bloating, and altered bowel habits. They are also at risk of complications such as acute diverticulitis, abscess formation, hemorrhage, and perforation. Intestinal dysbiosis and chronic inflammation have recently been recognized as potential key factors contributing to disease progression. Probiotics, due to their ability to modify colonic microbiota balance and to their immunomodulatory effects, could present a promising treatment option for patients with DD. CNCM I 1572 () is a probiotic strain with the capacity to rebalance gut microbiota and to decrease intestinal inflammation. This review summarizes the available clinical data on the use of in subjects with colonic DD.
憩室病(DD)是一种常见的胃肠道疾病。憩室病患者会经历各种各样的慢性非特异性症状,包括腹痛、腹胀和排便习惯改变。他们还面临诸如急性憩室炎、脓肿形成、出血和穿孔等并发症的风险。肠道生态失调和慢性炎症最近被认为是导致疾病进展的潜在关键因素。益生菌由于其能够调节结肠微生物群平衡及其免疫调节作用,可能为憩室病患者提供一种有前景的治疗选择。法国国家微生物保藏中心I 1572()是一种益生菌菌株,具有重新平衡肠道微生物群和减轻肠道炎症的能力。本综述总结了关于在患有结肠憩室病的受试者中使用的现有临床数据。